UY31235A1 - NEW PULVERULENT DRUGS CONTAINING TIOTROPY AND SALMETEROL, AS WELL AS LACTOSE AS EXCIPIENT - Google Patents

NEW PULVERULENT DRUGS CONTAINING TIOTROPY AND SALMETEROL, AS WELL AS LACTOSE AS EXCIPIENT

Info

Publication number
UY31235A1
UY31235A1 UY31235A UY31235A UY31235A1 UY 31235 A1 UY31235 A1 UY 31235A1 UY 31235 A UY31235 A UY 31235A UY 31235 A UY31235 A UY 31235A UY 31235 A1 UY31235 A1 UY 31235A1
Authority
UY
Uruguay
Prior art keywords
well
salmeterol
tiotropy
excipient
lactose
Prior art date
Application number
UY31235A
Other languages
Spanish (es)
Inventor
Christoph Kreher
Stephanie Ossadnik
Dr Michael Walz
Dr Michael Trunk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31235A1 publication Critical patent/UY31235A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A61M11/003—Particle size control by passing the aerosol trough sieves or filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A61M15/0025—Mouthpieces therefor with caps
    • A61M15/0026—Hinged caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere a preparaciones estables pulverulentas para la inhalacion, que contienen una sal de tiotropio y xinafoato de salmeterol, a procedimientos para su preparacion, así como su uso para la preparacion de un medicamento para el tratamiento de las vías aéreas, en especial para el tratamiento de EPOC (chronic obstructive pulmonary disease = enfermedad pulmonar obstructiva cronica) y asma.The invention relates to stable powdered preparations for inhalation, containing a salt of tiotropium and salmeterol xinafoate, to methods for its preparation, as well as its use for the preparation of a medicament for the treatment of the airways, especially for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.

UY31235A 2007-07-21 2008-07-17 NEW PULVERULENT DRUGS CONTAINING TIOTROPY AND SALMETEROL, AS WELL AS LACTOSE AS EXCIPIENT UY31235A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007034157 2007-07-21
US5193308P 2008-05-09 2008-05-09

Publications (1)

Publication Number Publication Date
UY31235A1 true UY31235A1 (en) 2009-03-02

Family

ID=39869109

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31235A UY31235A1 (en) 2007-07-21 2008-07-17 NEW PULVERULENT DRUGS CONTAINING TIOTROPY AND SALMETEROL, AS WELL AS LACTOSE AS EXCIPIENT

Country Status (9)

Country Link
US (1) US20100189780A1 (en)
EP (1) EP2182933B1 (en)
JP (1) JP2011509919A (en)
AR (1) AR067639A1 (en)
CA (1) CA2694479C (en)
PE (1) PE20090907A1 (en)
TW (1) TW200909004A (en)
UY (1) UY31235A1 (en)
WO (1) WO2009013244A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100638936B1 (en) * 2005-03-31 2006-10-25 엘지전자 주식회사 Cabinet structure of laundry dryer
EP3578169B1 (en) 2009-02-26 2024-06-26 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
EP2277799B8 (en) * 2009-07-23 2012-04-11 Airsec S.A.S. Hydrated humidity control substance and process for its preparation
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
ITRM20110083U1 (en) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire PLATE FOR THE CONSTRUCTION OF TRUCKS FOR AIRPLANES
MD4117C1 (en) * 2010-07-30 2012-02-29 Институт Химии Академии Наук Молдовы Powder with haemostatic and regenerative properties (variants) and process for the production thereof
EP2611423B2 (en) 2010-08-31 2022-09-21 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
EP3461474B1 (en) 2010-08-31 2020-11-11 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
GB201113662D0 (en) 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
ITMI20120092A1 (en) * 2012-01-26 2013-07-27 Micro Macinazione S A PHARMACO-CARRIER INCLUSION COMPOSITES PREPARED WITH MECHANICAL-CHEMICAL ACTIVATION PROCESS BY HIGH-ENERGY JET FLUID MILLS
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
US8545878B1 (en) 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
US9518050B2 (en) 2012-12-18 2016-12-13 Almirall, S.A. Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity
TWI643853B (en) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES
TW201517906A (en) 2013-07-25 2015-05-16 Almirall Sa Combinations comprising MABA compounds and corticosteroids
TWI641373B (en) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES
TW201617343A (en) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 New bicyclic derivatives having [beta]2 adrenergic agonist and M3 muscarinic antagonist activities
EP3206668A1 (en) * 2014-10-16 2017-08-23 Teva Branded Pharmaceutical Products R & D, Inc. Dry powder formulation
KR101748796B1 (en) * 2015-09-30 2017-06-19 한미약품 주식회사 Inhalation capsule with enhanced delivery rate of active ingredients
CA169756S (en) 2016-02-08 2017-09-01 Nicoventures Holdings Ltd Electronic cigarette
GB201605100D0 (en) 2016-03-24 2016-05-11 Nicoventures Holdings Ltd Vapour provision system
GB201605101D0 (en) 2016-03-24 2016-05-11 Nicoventures Holdings Ltd Electronic vapour provision system
GB201605105D0 (en) 2016-03-24 2016-05-11 Nicoventures Holdings Ltd Vapour provision apparatus
GB201605102D0 (en) 2016-03-24 2016-05-11 Nicoventures Holdings Ltd Mechanical connector for electronic vapour provision system
RU2741664C2 (en) 2016-07-22 2021-01-28 Никовенчерс Трейдинг Лимитед Case for device for providing vapour

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002822L (en) * 2000-08-04 2002-01-29 Microdrug Ag electrostatic Powder
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
JP3691459B2 (en) * 2002-06-14 2005-09-07 久光メディカル株式会社 Powder inhalant composition
DE10351663A1 (en) * 2002-12-20 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Stable, accurately dosable inhalable powder medicament for treating asthma or chronic obstructive pulmonary disease, containing tiotropium, specific form of salmeterol xinafoate and auxiliary
GB0520794D0 (en) * 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler

Also Published As

Publication number Publication date
EP2182933B1 (en) 2016-09-07
PE20090907A1 (en) 2009-08-05
EP2182933A1 (en) 2010-05-12
WO2009013244A1 (en) 2009-01-29
CA2694479C (en) 2016-09-13
AR067639A1 (en) 2009-10-21
US20100189780A1 (en) 2010-07-29
TW200909004A (en) 2009-03-01
JP2011509919A (en) 2011-03-31
CA2694479A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
UY31235A1 (en) NEW PULVERULENT DRUGS CONTAINING TIOTROPY AND SALMETEROL, AS WELL AS LACTOSE AS EXCIPIENT
ECSP055855A (en) INHALATION POWDER DRUGS CONTAINING A TIOTROPIO SALT AND SALMETEROLXINAFOATO
ECSP024268A (en) NEW POWDER FOR INHALATION CONTAINING TIOTROPY
WO2013021199A3 (en) Eutectic mixture for pulmonary administration
ECSP066544A (en) NEW TIOTROPE SALTS, PROCEDURES FOR PREPARATION, AS WELL AS MEDICINAL FORMULATIONS CONTAINING THEM
UY31686A1 (en) NEW DOSAGE AND FORMULATION
PE20160853A1 (en) COMBINED THERAPY FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
UY29506A1 (en) NEW CRYSTAL FORMS OF TIOTROPIO BROMIDE
CL2009000602A1 (en) Inhalable dry powder pharmaceutical composition comprising aclidinium bromide and a carrier, providing a nominal metered dose of aclidinium equivalent to about 400 micrograms of aclidinium bromide; its use in COPD and asthma; multi-dose dry powder inhaler device.
CL2007002099A1 (en) COMPOUNDS DERIVED FROM 3H-ESPIRO (1-BENZOFURAN-2,4'-PIPERIDINA); PREPARATION PROCESS; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF RESPIRATORY DISEASES, SUCH AS COPD AND ASTHMA.
ECSP066543A (en) NEW CRYSTAL ANHYDRATE WITH ANTICOLINERGIC ACTION
NO20051956L (en) Salmeterol superfine formulation
ECSP14028814A (en) NEW FORM OF DOSAGE AND FORMULATION OF ABEDITEROL
EA201590019A1 (en) DRY POWDER INHALERS, CARRIER CONTAINING, EXCELLENT FROM LACTOSE
CL2014003211A1 (en) Pharmaceutical composition for inhalation comprising aclidinium, with lactose, which provides a dose of 322 ug of free base and approx. 140 ug of aclidinium bromide; a method to treat a respiratory condition selected from asthma and epoc; use of the composition; and a calibrated dry powder inhaler device comprising it
ECSP055821A (en) NEW PULVERULENT FORMULATION CONTAINING INHALATION TIOTROPY
EA201201397A1 (en) INHALER CONTAINING DISTRIBUTED GLISTER PACKING
EA201201392A1 (en) PUSH-BUTTON DEVICE
EA201201393A1 (en) INHALER, DEVELOPED FOR DELIVERY OF MEDICINES AS DRY POWDER
UY28590A1 (en) PROCEDURE FOR THE PREPARATION OF NEW SALTS OF TIOTROPIO, NEW SALTS OF TIOTROPIO AS SUCH, AS WELL AS THE MEDICINAL FORMULATIONS CONTAINING THEM.
EA201590036A1 (en) COMPOSITIONS FOR DRY POWDER INHALER CONTAINING ANTAGONISTS OF MUSCARIN LONG TERM RECEPTORS
BR112015004810A2 (en) tiotropium preparations
TR200909788A2 (en) Dry powder formulation suitable for inhalation with tiotropium

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171011